샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794495

세계의 엠폭스 진단 시장

Mpox Diagnostics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 268 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 엠폭스 진단 시장은 2030년까지 22억 달러에 도달

2024년에 19억 달러로 추정되는 세계의 엠폭스 진단 시장은 2024-2030년의 분석 기간에 CAGR 2.7%로 성장하며, 2030년에는 22억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 항원 탐지 검사는 CAGR 2.1%를 기록하며, 분석 기간 종료까지 15억 달러에 달할 것으로 예측됩니다. 분자 검사 분야의 성장률은 분석 기간 중 CAGR 4.0%로 추정됩니다.

미국 시장은 5억 1,540만 달러로 추정, 중국은 CAGR 5.0%로 성장 예측

미국의 엠폭스 진단 시장은 2024년에는 5억 1,540만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년 CAGR을 5.0%로, 2030년까지 4억 2,610만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.0%와 2.0%로 예측됩니다. 유럽에서는 독일이 CAGR 1.5%로 성장할 것으로 예측됩니다.

세계의 엠폭스 진단 시장 - 주요 동향과 촉진요인 정리

Mpox의 진단 솔루션이 다시 주목받는 이유는 무엇인가?

질병 발생 패턴의 변화, 전 세계 감시 활동 증가, 사례 발견의 우선순위 변화로 인해 엠팍스 다이아그노스틱스는 다시 한 번 그 시급성이 대두되고 있습니다. 과거에는 천연두가 주로 특정 지역에서 유행하는 질병이었지만, 최근 수년간 국경을 초월한 감염으로 인해 적시에 진단하는 것이 공중 보건의 우선 순위가 되었습니다. 진단은 초기 사례 격리, 발병 추적, 접촉자 추적에 있으며, 핵심적인 역할을 합니다. 신속성과 정확성을 보장하기 위해 현재 진단 툴은 기존의 혈청학적 접근법 대신 병변 기반 샘플링에 초점을 맞추었습니다.

실험실 검사는 주로 핵산 증폭법에 의존하고 있습니다. 이 방법은 피부 병변이나 딱지에 포함된 바이러스 DNA의 존재를 감지합니다. 검사 정확도가 가장 높은 것은 활성 병변 부위에서 검체를 채취하는 경우로, 혈액 검체에서 얻을 수 있는 바이러스 양의 잠재적 편차를 피할 수 있습니다. 특히 고급 검사 인프라에 대한 접근이 제한된 지역에서는 빠르고 신뢰할 수 있는 분산형 검사를 가능하게 하는 툴에 초점을 맞추었습니다. 검체 채취를 간소화하고 처리 시간을 단축하는 것은 새로운 진단 플랫폼에서 점점 더 중요한 설계 요소가 되고 있습니다.

PCR 기반 검사가 현재 진료의 벤치마크가 되는 이유는 무엇인가?

PCR 기반 검사는 여전히 정확한 수두 진단의 기초가 되고 있습니다. 이 방법은 민감하고 특이적이며, 소량의 바이러스 DNA로도 검출할 수 있습니다. 실시간 PCR 검사는 현재 임상 현장과 공중 보건 연구소에서 사용되는 가장 신뢰할 수 있는 플랫폼입니다. 이 검사들은 수두 바이러스 유전체의 특정 영역을 타겟으로 하고 있으며, 수두 바이러스 클레이드를 구분하고 감염 상태를 확인할 수 있습니다. PCR 시스템에는 실험실 기반 분석 장비부터 현장 진료용으로 설계된 휴대용 카트리지형 장비까지 여러 가지 유형이 있습니다.

접근성을 개선하고 소요 시간을 단축하기 위해 새로운 분자진단 플랫폼이 등장하고 있습니다. 일부는 1시간 이내에 검사할 수 있는 제품도 있으며, 발병시 신속한 의사결정을 지원합니다. 이러한 시스템은 신속한 환자 분류 및 격리가 필요한 경우에 특히 유용합니다. 중앙 집중식 검사 외에도 휴대용 분자 플랫폼은 야전 병원, 국경 입구, 이동식 위생 유닛에서 사용하기 위해 관련성을 높이고 있습니다. 조작의 편의성, 최소한의 기술 교육, 기존 의료 워크플로우와의 호환성에 중점을 두고 있습니다.

항원 신속 검사가 진단 기준을 충족하지 못한 이유는 무엇인가?

항원 기반 신속 진단 검사는 아직 수두 검출의 신뢰성이 입증되지 않았습니다. 높은 특이성을 보이는 것도 있지만, 민감도는 일관되게 낮습니다. 대부분의 항원 검사는 특히 감염 초기나 치유기의 낮은 바이러스 양을 검출하는 데 어려움을 겪고 있습니다. 무증상 또는 전증상 사례를 감지할 수 없기 때문에 감시 및 조기 대응에 사용하는 데 한계가 있습니다. 이러한 제약으로 인해 단독 진단보다는 보조적인 스크리닝으로 역할이 제한됩니다. 이러한 제약으로 인해 보건 당국은 현재 이러한 검사를 임상적으로 사용하는 것을 승인하지 않고 있습니다.

이러한 격차에 따라 개발 노력은 개선된 분자 툴와 새로운 검출 기술로 전환되고 있습니다. 현재는 분자 검출과 디지털 디스플레이 및 원격 모니터링 기능을 결합한 진단 툴도 있습니다. 병변 사진을 평가하기 위해 AI 지원 이미지 인식을 이용한 실험적 시스템도 평가되고 있습니다. 이 툴들은 검사 시설을 이용할 수 없는 원격지에서의 진단을 지원하는 것을 목적으로 합니다. 그러나 이러한 시스템을 널리 사용하려면 더 많은 임상적 검증이 필요합니다.

엠팍스 다이애그노스틱스 시장 성장의 원동력은 무엇인가?

엠팍스 다이애그노스틱스 시장의 성장은 몇 가지 요인에 의해 이루어집니다. 발병 빈도가 증가하고 지역적 범위가 넓어짐에 따라 더 빠른 감지 툴에 대한 수요가 증가하고 있습니다. Point-of-Care PCR 장비의 사용 확대로 농촌 및 저자원 환경에서의 검사 지연이 감소하고 있습니다. 발병 대응 키트에 분자진단법을 접목하여 조기 봉쇄를 가능하게 하고 있습니다. 대규모 검사실 인프라를 필요로 하지 않는 휴대용 플랫폼에 대한 투자가 증가하면서 신규 진출기업 시장 진입을 촉진하고 있습니다.

분산형 검사 및 모바일 진단이 강조되면서 개발도상국의 공중보건 목표에 부합하고 있습니다. 검사 결과를 감시 데이터베이스와 연계하는 디지털 헬스 툴의 보급도 효율적인 발병 관리에 기여하고 있습니다. 다른 피부질환 및 발열성 질환과의 중복 증상으로 인한 감별진단의 필요성이 증가함에 따라 고특이도 분석의 중요성이 높아지고 있습니다. 새로운 진단 플랫폼의 긴급 사용에 대한 지속적인 제품 승인과 규제 지침은 제품 혁신과 지역적 접근성을 지속적으로 지원하고 있습니다.

부문

진단 테스트(항원 탐지 테스트, 분자 테스트); 샘플(뇨샘플, 전혈샘플, 피부병변 검체 샘플)

조사 대상 기업의 예

  • Abbott Laboratories
  • ACON Biotech(Hangzhou)
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Cepheid(Danaher Corporation)
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer(Alinity(TM) m MPXV assay)
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장과 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Mpox Diagnostics Market to Reach US$2.2 Billion by 2030

The global market for Mpox Diagnostics estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Antigen Detection Test, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Molecular Test segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$515.4 Million While China is Forecast to Grow at 5.0% CAGR

The Mpox Diagnostics market in the U.S. is estimated at US$515.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$426.1 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Mpox Diagnostics Market - Key Trends & Drivers Summarized

Why Is There Renewed Focus on Diagnostic Solutions for Mpox?

Mpox diagnostics have gained renewed urgency due to changing patterns in disease outbreaks, increasing global surveillance efforts, and a shift in case detection priorities. Earlier, mpox was largely endemic to specific regions, but recent cross-border transmission has made timely diagnosis a public health priority. Diagnosis plays a central role in early case isolation, outbreak tracking, and contact tracing. To ensure speed and accuracy, diagnostic tools now focus on lesion-based sampling rather than traditional serological approaches.

Laboratory testing continues to rely primarily on nucleic acid amplification methods. These techniques detect the presence of viral DNA in skin lesions and scabs. Testing accuracy is highest when samples are collected from active lesions, avoiding potential variability in viral load from blood samples. Focus has shifted toward tools that allow rapid, reliable, and decentralized testing, particularly in regions with limited access to advanced laboratory infrastructure. Simplification of sample collection and faster processing times are increasingly important design factors for new diagnostic platforms.

What Makes PCR-Based Testing the Benchmark in Current Practice?

PCR-based testing remains the foundation for accurate mpox diagnosis. This method is highly sensitive and specific, detecting even low quantities of viral DNA. Real-time PCR assays are currently the most trusted platform used in clinical settings and public health laboratories. These tests target specific regions of the mpox virus genome, allowing differentiation between clades and confirmation of infection status. Several types of PCR systems exist, ranging from lab-based analyzers to portable, cartridge-based units designed for point-of-care use.

New molecular diagnostic platforms are emerging to improve access and reduce turnaround times. Some allow testing in under one hour, supporting faster decision-making in outbreak settings. These systems are particularly useful where rapid patient triage and isolation are needed. In addition to centralized testing, portable molecular platforms are gaining relevance for use in field hospitals, border entry points, and mobile health units. Emphasis remains on operational simplicity, minimal technical training, and compatibility with existing healthcare workflows.

Why Have Rapid Antigen Tests Failed to Meet Diagnostic Standards?

Antigen-based rapid diagnostic tests have not yet proven reliable for mpox detection. While some show high specificity, their sensitivity is consistently low. Most antigen tests struggle to detect lower viral loads, especially in early or healing stages of infection. Their inability to detect asymptomatic or pre-symptomatic cases limits their use in surveillance or early response. This limitation restricts their role to supplementary screening rather than standalone diagnosis. Due to these constraints, health authorities do not currently endorse these tests for clinical use.

In response to these gaps, development efforts are shifting toward improved molecular tools and novel detection technologies. Some diagnostic tools now combine molecular detection with digital readouts or remote monitoring features. Experimental systems using AI-assisted image recognition to assess lesion photographs are also being evaluated. These tools aim to support diagnosis in remote locations where laboratory facilities are unavailable. However, such systems require further clinical validation before they can be used widely.

What Factors Are Driving Growth in the Mpox Diagnostics Market?

Growth in the mpox diagnostics market is driven by several factors. Rising frequency of outbreaks and their geographic spread has increased the demand for faster detection tools. Expanded use of point-of-care PCR devices is helping reduce testing delays in rural and low-resource settings. Integration of molecular diagnostics into outbreak response kits is enabling early containment. Increased investment in portable platforms that operate without extensive laboratory infrastructure is encouraging market participation from new manufacturers.

Greater emphasis on decentralized testing and mobile diagnostics is aligning with public health goals in developing countries. Uptake of digital health tools that link test results with surveillance databases is also contributing to efficient outbreak management. Growing need for differential diagnosis due to overlapping symptoms with other skin or febrile illnesses is raising the importance of high-specificity assays. Ongoing product approvals and regulatory guidance for emergency use of new diagnostic platforms continue to support product innovation and regional accessibility.

SCOPE OF STUDY:

The report analyzes the Mpox Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnostic Test (Antigen Detection Test, Molecular Test); Sample (Urine Sample, Whole Blood Sample, Skin Lesion Specimen Sample)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • ACON Biotech (Hangzhou)
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Cepheid (Danaher Corporation)
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer (Alinity(TM) m MPXV assay)
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mpox Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Mpox Infections Spurs Demand for Rapid and Accurate Diagnostic Solutions
    • Government Surveillance Programs and Outbreak Preparedness Plans Drive Adoption of Diagnostic Testing
    • Technological Advancements in Point-of-Care Testing Strengthen Accessibility in Resource-Limited Settings
    • Integration of PCR and Isothermal Amplification Methods Propels Market for Molecular Mpox Diagnostics
    • Public Health Emergency Declarations Throw Spotlight on Fast-Tracking of Diagnostic Product Approvals
    • Expansion of Travel Screening and Quarantine Protocols Generates Demand for Portable Test Kits
    • Increasing Role of Central Laboratories in Outbreak Control Sustains Market for High-Throughput Systems
    • Demand for Cost-Effective Testing Solutions in Developing Nations Fuels Adoption of Lateral Flow Assays
    • Healthcare Worker Safety Protocols Drive Investment in Biosafe Sample Collection and Handling Tools
    • Growth in Zoonotic Disease Surveillance Expands Market Opportunity for Cross-Species Diagnostic Platforms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mpox Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antigen Detection Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Molecular Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Whole Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Skin Lesion Specimen Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • JAPAN
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • CHINA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • EUROPE
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • FRANCE
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • GERMANY
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • INDIA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Mpox Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Mpox Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • AFRICA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제